17 -8 (58) 2023 — Egamova Sitora Кobilovna — CLINICAL AND PROGNOSTIC SIGNIFICANCE OF TP53 GENE MUTATION IN ACUTE LEUKEMIA

CLINICAL AND PROGNOSTIC SIGNIFICANCE OF TP53 GENE MUTATION IN ACUTE LEUKEMIA

Egamova Sitora Кobilovna Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

 The frequency, structural features and prognostic value of TP53 gene mutations in acute myeloid and lymphoblastic leukemias were analyzed. Mutations were detected using the PCR diagnostic method. It was found that the average frequency of TP53 mutations in acute myeloid leukemia is 9,7% and varies depending on the cytogenetic variant and the presence of other genetic abnormalities. The maximum frequency of TP53 mutations (60%) was found in acute myeloid leukemia with complex chromosomal aberrations. The frequency of TP53 mutations in acute lymphoblastic leukemia was 2,2%. The prognosis of the program treatment of acute leukemia with TP53 mutations was extremely unfavorable: the median of the total life expectancy of patients did not exceed 3 months.

Keywords: acute leukemia, TP53 gene, mutation, prognosis

First page

99

Last page

102

For citation: Egamova Sitora Кobilovna – CLINICAL AND PROGNOSTIC SIGNIFICANCE OF TP53 GENE MUTATION IN ACUTE LEUKEMIA //New Day in Medicine 2023 8(58): 99-102 https://newdaymedicine.com/index.php/2023/08/16/l-305/

LIST OF REFERENCES:

1. Блау О.В. Мутации генов при острых миелоидных лейкозах. //Клиническая онкогематология. 2016;9(3):245-256.
2. Виноградов А.А., Резайкин А.В. Прогностистическое значение мутаций гена ТР53 при прогроммном лечении больных острыми лейкозами. //Вестник РОНЦ им. Н.Н. Блохина РАМН. 2013;24(2):33-40.
3. Каримов Х.Я., Пулатова Н.С. Роль полиморфизма rs1042522 гена-супрессора опухолевого роста TP53 в онкогенезе ОМЛ. //Вестник гематологии. 2019;37-38.
4. Козич Ж.М., Новик Д.К. Прогностические значение молекулярно-генетических маркеров при остром миелобластном лейкозе. //Проблемные статьи и обзоры. 2015;9;4-6.
5. Egamova S.K. Cytogenetics in acute leukemia. //New day in medicine. Bukhara, 2021;6(38):244-249.
6. Egamova S.K. Algoritm for the diagnosis of acute leukemia. //British medical journal. London, 2021.-№2. Р.160-174.
7. Egamova S.K., Boboev K.T. Рrognostic significance of genetic mutations in patients with acute leukemia. //NeuroQuantology, 2022;20:1093-1097.
8. Hunter A.M., Sallman D.A. Current status and new treatment approaches in TP53 mutated AML. //Best Pract Res Clin Haematol. 2019;32(2):134-144.
9. Kadia T.M., Jain P., Ravandi F. et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. //Cancer. 2016;122(22):3484-3491.
10. Short N.J., Montalban-Bravo G., Hwang H. et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. //Blood Adv. 2020;4(22):5681-5689.
11. Zhang L., McGraw K.L., Sallman D.A., List A.F. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. //Leuk Lymphoma. 2017;58(8):1777-1790.